Immuron (IMRN) Operating Expenses (2016 - 2024)
Immuron (IMRN) posted quarterly Operating Expenses of -$2772.7 billion for Q4 2024, down 60245866.88% year-over-year from N/an in Q1 2024, and down 60245866.88% quarter-over-quarter from -$4.6 million in Q4 2023.
Immuron (IMRN) Operating Expenses (2016 - 2024) Analysis & Trends
Immuron's Operating Expenses history runs 9 years deep, the most recent figure standing at -$2772.7 billion for Q4 2024.
- In Q4 2024, Operating Expenses fell 60245866.88% year-over-year to -$2772.7 billion; the TTM figure through Sep 2025 stood at -$2772.7 billion (down 60245866.88% YoY), while the FY2025 annual figure was $5.2 million, down 19.59% from the prior year.
- Operating Expenses for Q4 2024 stood at -$2772.7 billion, down from -$4.6 million in the prior quarter.
- The five-year high for Operating Expenses was $337933.8 in Q4 2020, with the low at -$2772.7 billion in Q4 2024.
- The 5-year median for Operating Expenses is -$501311.3 (2022), against an average of -$462.1 billion.
- The sharpest annual moves came in 2021 and 2024: Operating Expenses slipped 26.05% in 2021, then tumbled 60245866.88% in 2024.
- Immuron's Operating Expenses stood at $337933.8 in 2020, then declined by 26.05% to $249911.6 in 2021, then tumbled by 199.22% to -$247958.7 in 2022, then tumbled by 1756.08% to -$4.6 million in 2023, then sank by 60245866.88% to -$2772.7 billion in 2024.
- Business Quant data shows IMRN's Operating Expenses at -$2772.7 billion in Q4 2024, -$4.6 million in Q4 2023, and -$754663.8 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Immuron | 6.81 Mn | 6.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2,772.71 Bn |
| Dec 31, 2023 | -4.60 Mn |
| Jun 30, 2023 | -754,663.83 |
| Dec 31, 2022 | -247,958.71 |
| Dec 31, 2021 | 249,911.60 |
| Dec 31, 2020 | 337,933.81 |
| Dec 31, 2019 | 509,279.32 |
| Dec 31, 2018 | -674,963.00 |
| Dec 31, 2017 | -3.27 Mn |
| Dec 31, 2016 | -2.19 Mn |
| Jun 30, 2016 | -3.69 Mn |